Research Overview
Extensive Benefits of Biopharmaceuticals Promote Increased
Manufacturing
Biopharmaceuticals offer numerous advantages that are driving enhanced
production on a worldwide basis. For instance, they have a stronger focus on
target diseases and provide more effective and potent action. They also entail
fewer side effects and have great potential to actually cure diseases rather
than merely treat the symptoms. Moreover, biopharmaceuticals ? which are
generally injected directly into the blood stream and are very fragile molecules
? degenerate very easily in the human digestive system. With the growing number
of new diseases that can be treated with biopharmaceuticals, the demand for
these drugs is on the increase, leading to increased manufacturing.
This Frost & Sullivan strategic analysis service provides global coverage
of the manufacturing capabilities of biopharmaceuticals. It provides detailed
quantification of the supply and demand for production capacities. It also
examines the demand-supply balance and offers strategic recommendations to
address the challenges arising from the inequalities in this balance.
Understanding the Demand-Supply Balance of Manufacturing Capacities Vital
for Biopharmaceuticals Industry Progression
"The capacity gap - which is the difference between the supply and
demand of manufacturing capacities - presents a fundamental challenge to the
industry," observes the analyst of this research service. "Deficit of
capacity is likely to significantly affect industry progression."
Biopharmaceuticals developers need to understand the existing capacity gap in
the market as well as evaluate their own financial positions. Based on this
demand-supply situation, they can enter into long-term contracts with contract
manufacturing organisations (CMOs) or invest in building manufacturing plants.
Frost & Sullivan estimates that the global manufacturing capacity ?
Including that held by captive use and contract manufacturers ? Will grow from
2.27 million litres in 2004 to 3.69 million litres in 2011 at a compound annual
growth rate (CAGR) of 7.2 per cent. The global demand for manufacturing
capacity, on the other hand, stands at 1.37 million litres in 2004 and is likely
to increase to 3.13 million litres in 2011. Currently, there is overcapacity in
the industry with capacity utilisation pegged at around 60 per cent. This is
likely to increase to 70 per cent by the end of 2006 and 80 per cent in 2008,
after which demand will continue to rise due to key drug approvals.
Drying Product Pipeline and Absence of Intellectual Property Laws are
Causes for Concern
"Resource and product portfolio management is proving to be a key
challenge to the biopharmaceuticals industry," says the analyst.
"There are growing concerns about the drug pipeline drying up in the
pharmaceuticals industry and this extends to biopharmaceuticals as well."
Additionally, the lack of internationally accredited intellectual property laws
or patent models prevents companies from innovating and causes them to limit
application to certain countries only.
Companies will have to collaborate with academics to clarify the patents
required for a particular licence. Subsequently, keeping a track of developments
in the areas where they have filed for patents is essential. Only then will
companies be able to realise the full potential of this industry.
Frost & Sullivan Growth Partnership Service
Based on extensive and in-depth research, real-world consulting work, and new
theories tested in hundreds of companies across many industries, Frost &
Sullivan has evolved its Growth Partnership Services (GPS) programme that
provides established and emerging firms with powerful growth visions. Moving
beyond token mission statements, GPS provides an actionable vision to growth
consulting partners by illustrating how key intelligence and strategic research
based on defined goals can guide day-to-day behaviour and overall company
direction. The foundation of Frost & Sullivans GPS includes:
- Assisting companies to reach their full potential in the core business
- Providing growth strategies to help companies expand into related
businesses
- Preemptively redefining the core business during market turbulence
- Applying the Frost & Sullivan framework to identify and address common
mistakes resulting from misaligned corporate strategies
- Recommending growth management strategies through continuous partnership
To maximise the potential for growth within a firms internal and external
environment, Frost & Sullivan consultants can facilitate the creation of
strategic programmes that deliver improved market success. Frost &
Sullivans strengths lie in combining strategic understanding with market
expertise and applying these with absolute commitment to its clients growth.
View Cart
